|
Adenocarcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
After microdissecting and testing the adenocarcinoma and neuroendocrine components separately, it was found that the adenocarcinoma was positive for KRAS G12C mutation and the neuroendocrine component was positive for KRAS G12D mutation.
|
27597976 |
2016 |
|
Adenocarcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
In addition, KRAS gene exon 2 G12C presented mutation in the OSP-associated adenocarcinoma.
|
29879069 |
2018 |
|
Adenocarcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Seven of 17 cases (41%) were reclassified in the adenocarcinoma with solid pattern group, which showed one KRAS G12C and one EGFR E709K + G719C double mutation in addition to mutations in TP53.
|
26430808 |
2016 |
|
Adenocarcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Analysis of the KRAS gene showed only a G12C variation in one large cell carcinoma (LCC) patient, whereas variants were not found in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) cases.
|
30048458 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
CLINVAR |
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
|
25044103 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
BEFREE |
<i>KRAS p.G12C</i>, which occurs in approximately 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors.
|
31531201 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
BEFREE |
KRAS-G12C mutation is associated with worse DFS and OS in resected lung AC.
|
25170638 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
BEFREE |
Presence of the KRAS G12C mutation had 96% specificity and positive predictive value for lung adenocarcinoma, whereas G12R was 99% specific for pancreatic cancer with a positive predictive value of 86%.
|
23887294 |
2014 |
|
Adenoid Cystic Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Adenoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS mutations were identified in 24% MUTYH-associated-polyposis vs 15% classical/attenuated familial polyposis adenomas; mutated MUTYH-associated-polyposis adenomas exhibited only c.34G>T transversions in codon 12, an alteration typically associated with oxidative DNA damage, or mutations in codon 13; neither of these mutations was found in classical/attenuated familial polyposis adenomas (P<0.001).
|
23599153 |
2013 |
|
Adenomatous Polyposis Coli
|
|
0.020 |
GeneticVariation
|
BEFREE |
The c.34G>T was present in 39.7% of MAP adenomas versus 1.6% of FAP adenomas (P < 0.01).
|
26056087 |
2015 |
|
Adenomatous Polyposis Coli
|
|
0.020 |
GeneticVariation
|
BEFREE |
KRAS mutations were identified in 24% MUTYH-associated-polyposis vs 15% classical/attenuated familial polyposis adenomas; mutated MUTYH-associated-polyposis adenomas exhibited only c.34G>T transversions in codon 12, an alteration typically associated with oxidative DNA damage, or mutations in codon 13; neither of these mutations was found in classical/attenuated familial polyposis adenomas (P<0.001).
|
23599153 |
2013 |
|
Adult Diffuse Large B-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.
|
9139869 |
1997 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
|
0.010 |
GeneticVariation
|
BEFREE |
In explant cells derived from these PDX tumor models with a KRAS G12R mutation, treatment with inhibitors of CDKs (including CDK9) reduced phosphorylation of a marker of CDK9 activity (phospho-RNAPII CTD Ser2/5) and reduced viability/growth of explant cells derived from PDAC PDX models.
|
26934555 |
2016 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
|
0.010 |
GeneticVariation
|
BEFREE |
Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene.
|
9139869 |
1997 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour.
|
28594414 |
2017 |
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
|
Carcinoma of lung
|
|
0.880 |
CausalMutation
|
CLINVAR |
|
|
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |